Abstract 102P
Background
In view of a higher likelihood of risk of having advanced adenoma or invasive cancer in the individual with above average, we investigated whether receiving subsequent faecal immunochemical tests (FITs) in the intervals between colonoscopies could reduce the risk of colorectal cancer (CRC) and advanced colorectal neoplasia (ACN) incidence.
Methods
A retrospective cohort study was performed among high-risk population for CRC between January 2012 and December 2022, in Tianjin, China. The incidence of CRC and ACN were calculated for the FIT surveillance and non-FIT surveillance groups and reported as the number of events per 100000 person-years. Cox proportional hazards model models were applied to evaluate the risks of CRC and ACN, with crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CI).
Results
We included 12515 participants with a high risk of CRC, aged 40-74 years, of whom 4980 received subsequent FIT between colonoscopies during the study period. Among these participants, 51 CRC cases occurred in the non-FIT surveillance group (incidence rate, 233.88 per 100000 person-years) and there were 29 cases of CRC in the FIT surveillance group (incidence rate, 184.85 per 100000 person-years). The cumulative events of the advanced adenoma group were highest, followed by the non-advanced adenoma group, then the no neoplasia group stratified based on the prior colonoscopy findings. Compared with the non-FIT surveillance group, the FIT surveillance group had a 54% decreased risk of developing CRC (HR, 0.46; 95% CI, 0.29-0.74) and a 45% decreased risk of developing ACN (HR, 0.55; 95% CI, 0.47-0.64).
Conclusions
In this CRC surveillance program, our study found that high-risk participants who received subsequent FIT surveillance in the intervals between colonoscopy were associated with a reduction of CRC and ACN incidence, which indicated the value and utility of FIT in the surveillance program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant. No: 81973135 and 81972826) and Science and Technology Commission of Shanghai Municipality (Grant. No: 21XD1402600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract